Spero Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -101.7% | -101.7% | -52.5% |
| FY2022 | -61.1% | -61.1% | -37.2% |
| FY2023 | 21.3% | 21.3% | 12.5% |
| FY2024 | -148.7% | -148.7% | -62.0% |
| FY2025 | 14.5% | 14.5% | 12.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -101.7% | -101.7% | -52.5% |
| FY2022 | -61.1% | -61.1% | -37.2% |
| FY2023 | 21.3% | 21.3% | 12.5% |
| FY2024 | -148.7% | -148.7% | -62.0% |
| FY2025 | 14.5% | 14.5% | 12.4% |